Funds will enable the company to finalize the regulatory process toward CE certification for its ophthalmology platform, which provides pre-diagnostics and patient triage.
BlueOcean Ventures invests in MIKAJAKI, inventor of the world’s first ophthalmic diagnostic robotic platform
April 24, 2020
|In News